Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)
View on Grants.gov ↗ Sign in to save
- Type
- Grant
- Notice type
- CA
- Agency
- National Institutes of Health
- Sub-agency
- HHS-NIH11
- Solicitation #
- RFA-NS-28-012
- Posted
- Nov 3, 2026
- Response due
- Oct 10, 2028
- Archive date
- Dec 9, 2028
- CFDA / Assistance listing
- 93.866,93.NS1
- Award ceiling
- $2,500,000
- Total program funding
- $6,000,000
- Contact
- nindsdonadrd@mail.nih.gov
- Source
- Grants.gov
Description
This Notice of Funding Opportunity (NOFO) supports the translation of genome editing and other biologic therapies for Alzheimer's Disease-Related Dementias (ADRD). The program spans the full translational pipeline, from therapeutic lead optimization and drug product development through IND-enabling studies and early clinical evaluation. Supported activities may include optimization of editing constructs and delivery systems; assessment of bioactivity, target engagement, durability, pharmacokinetics, and bioavailability; demonstration of in vivo efficacy; execution of safety pharmacology and toxicology studies; and development of scalable manufacturing processes, formulation strategies, and quality attributes aligned with regulatory expectations.ADRD include Frontotemporal Dementia (FTD); Lewy Body Dementias (LBD), including Dementia with Lewy Bodies (DLB) and Parkinson's Disease Dementia (PDD); Vascular Contributions to Cognitive Impairment and Dementia (VCID); and Multiple Etiology Dementias (MED).